Biotech Values

[DewDiligence]

I didn’t offer such a number, but it would not be unduly hard to calculate. You need to specify a discount rate to apply to future cash flows and to make some assumptions about other competitors. I presume that if MNTA settled with Amphastar, MNTA could settle with any other generic entrant on the same or better terms. I think it’s also safe to assume that SNY will not launch an authorized generic while MNTA’s generic is the only one in the market.